In the BioHarmony Drug Report Database
Cyclosporine
Cequa, Neoral, Restasis, Restasis Multidose, Sandimmune, Verkazia, Ikervis (cyclosporine) is a protein pharmaceutical. Cyclosporine was first approved as Cequa on 1983-11-14. It is used to treat focal segmental glomerulosclerosis, myasthenia gravis, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus in the USA. It has been approved in Europe to treat conjunctivitis, corneal diseases, and keratitis. The pharmaceutical is active against peptidyl-prolyl cis-trans isomerase A. In addition, it is known to target solute carrier organic anion transporter family member 1B3, solute carrier organic anion transporter family member 1B1, fMet-Leu-Phe receptor, sodium/bile acid cotransporter, broad substrate specificity ATP-binding cassette transporter ABCG2, and peptidyl-prolyl cis-trans isomerase D. Sandimmune’s patents are valid until 2037-02-28 (FDA).
Trade Name
|
Ikervis, Verkazia |
|---|---|
Common Name
|
cyclosporine |
ChEMBL ID
|
CHEMBL160 |
Indication
|
conjunctivitis, corneal diseases, focal segmental glomerulosclerosis, keratitis, myasthenia gravis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus |
Drug Class
|
Immunosuppressantcalcineurin inhibitoreye medication |
Image (chem structure or protein)